Guilford Extends Gliadel Payment Schedule To Boost Hospital Availability
Executive Summary
Guilford Pharmaceuticals will extend the payment terms for hospitals purchasing the Gliadel Wafer to encourage wider use of the product.
You may also be interested in...
Guilford Seeks To Triple Gliadel Market With First-Line Indication
Approval of Guilford Pharmaceuticals' Gliadel Wafer for first-line treatment of metastatic brain cancer could triple use of the product, the company reported.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials